Buffett plans to attend, but not take questions, at next year's Berkshire shareholder meeting
OMAHA, Neb. (AP) — Billionaire Warren Buffett plans to attend, but not take questions, at next year's Berkshire Hathaway shareholder meeting — a big change following his recent surprise retirement announcement.
Buffett's handpicked successor, Greg Abel, told the Omaha World-Herald that Berkshire plans a shareholder meeting for the first weekend of May that will have a question-and-answer session. But Buffett, who plans to remain as Berkshire's chairman, plans to sit with the conglomerate's board of directors and not be on stage taking questions.
The annual shareholder meeting attracts some 40,000 people to Omaha in what's been dubbed 'Woodstock for Capitalists." The marathon Q&A sessions held by Buffett, the world's most important investor known for his wit and self-effacing humor, have been a major draw.
The 94-year-old Buffett shocked an arena full of shareholders earlier this month by announcing at the end of a five-hour Q&A that he will retire at the end of the year. Susie Buffett, Buffett's daughter, told the World-Herald that Buffett wants Abel to handle the question-and-answer sessions going forward.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Investors in Orica (ASX:ORI) have seen returns of 27% over the past three years
Investors can buy low cost index fund if they want to receive the average market return. But across the board there are plenty of stocks that underperform the market. Unfortunately for shareholders, while the Orica Limited (ASX:ORI) share price is up 17% in the last three years, that falls short of the market return. In the last year the stock price gained, albeit only 3.3%. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Orica became profitable within the last three years. That would generally be considered a positive, so we'd expect the share price to be up. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that Orica has improved its bottom line over the last three years, but what does the future have in store? You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Orica's TSR for the last 3 years was 27%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence! Orica shareholders gained a total return of 6.3% during the year. But that return falls short of the market. The silver lining is that the gain was actually better than the average annual return of 5% per year over five year. It is possible that returns will improve along with the business fundamentals. It's always interesting to track share price performance over the longer term. But to understand Orica better, we need to consider many other factors. Take risks, for example - Orica has 2 warning signs we think you should be aware of. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
PORTLAND, Ore. (AP) — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks the court's approval to buy the struggling firm. Biological samples, DNA data, health-related traits and medical records are too sensitive to be sold without each person's express, informed consent, Oregon Attorney General Dan Rayfield said in a news release about the lawsuit. Customers should have the right to control such deeply personal information and it cannot be sold like ordinary property, it said. 23andMe customers use saliva-based DNA testing kits to learn about their ancestry and find long-lost relatives. Founded in 2006, the company also conducted health research and drug development. But it struggled to find a profitable business model since going public in 2021. In March it laid off 40% of its staff and filed for Chapter 11 bankruptcy protection in the Eastern District of Missouri, raising concerns about the safety of customer data. Regeneron Pharmaceuticals said last month it aimed to buy the company for $256 million. Regeneron said it would comply with 23andMe's privacy policies and applicable law. It said it would process all customer personal data in accordance with the consents, privacy policies and statements, terms of service, and notices currently in effect and have security controls in place designed to protect such data. A court-appointed, independent consumer privacy ombudsman was due to examine the proposed sale and how it might affect consumer privacy and report to the court by Tuesday.
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
PORTLAND, Ore. (AP) — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks the court's approval to buy the struggling firm. Biological samples, DNA data, health-related traits and medical records are too sensitive to be sold without each person's express, informed consent, Oregon Attorney General Dan Rayfield said in a news release about the lawsuit. Customers should have the right to control such deeply personal information and it cannot be sold like ordinary property, it said. 23andMe customers use saliva-based DNA testing kits to learn about their ancestry and find long-lost relatives. Founded in 2006, the company also conducted health research and drug development. But it struggled to find a profitable business model since going public in 2021. In March it laid off 40% of its staff and filed for Chapter 11 bankruptcy protection in the Eastern District of Missouri, raising concerns about the safety of customer data. Regeneron Pharmaceuticals said last month it aimed to buy the company for $256 million. Regeneron said it would comply with 23andMe's privacy policies and applicable law. It said it would process all customer personal data in accordance with the consents, privacy policies and statements, terms of service, and notices currently in effect and have security controls in place designed to protect such data. A court-appointed, independent consumer privacy ombudsman was due to examine the proposed sale and how it might affect consumer privacy and report to the court by Tuesday.
